We are thrilled to share some groundbreaking news with you! As a leading biotechnology company, dedicated to providing top-tier raw materials for cutting-edge applications in cell and gene therapy, vaccine manufacturing, IVD, and laboratory research, we are excited to announce a significant achievement within our network.

Two of our esteemed partners in the field of cell therapy have recently obtained regulatory approvals from TFDA (Taiwan Food and Drug Administration) for their revolutionary treatments. What sets this accomplishment apart is the pivotal role played by our GMP grade recombinant proteins in their success.

Our partners have utilized our GMP IL-2, alongside other top-quality recombinant proteins, to develop their cell therapy solutions. These proteins are crucial components in the manufacturing process, ensuring the production of safe and effective therapies that meet the highest regulatory standards.

This milestone not only underscores the remarkable progress of our partners but also highlights the critical role played by our GMP grade recombinant proteins in advancing the field of regenerative medicine. By leveraging our expertise and high-quality products, our partners have been able to develop innovative cell therapy treatments that are now approved for clinical use.

At Croyez Bioscience, we take immense pride in our contribution to the advancement of healthcare through our premium-grade raw materials. Our commitment to excellence and innovation remains unwavering as we continue to support our partners and customers in their pursuit of scientific breakthroughs.

We invite you to join us in celebrating this momentous achievement and look forward to further collaborations that drive progress and innovation in the biotechnology industry.

Stay connected with Croyez Bioscience for the latest updates and developments as we continue to push the boundaries of possibility in biomedicine. Thank you for your ongoing support and trust in our brand.